Showing results (61-70 of 74) with videos related to
Sort By:
Pageof 8
Chemical Science|September 12, 2022
Establishing the selective phospholipid membrane coordination, permeation and lysis properties for a series of 'druggable' supramolecular self-associating antimicrobial amphiphilesJessica E Boles, Charlotte Bennett, Jennifer Baker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid TumorsRobert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos, et al.Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.The Biochemical Journal|October 14, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathwayJill E Hunter, Amy E Campbell, Nicola L Hannaway, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.Journal of Materials Chemistry. B|June 16, 2025
Towards the development of supramolecular self-associating amphiphiles as antibiofilm agents against Pseudomonas aeruginosa and Candida albicans biofilmsKira L F Hilton, Hendrik J F Steyn, Kusasalethu S Luthuli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkersTimothy A Yap, Li Yan, Amita Patnaik, et al.Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.Chemical Science|March 12, 2026
Amino acid appended supramolecular self-associating amphiphiles demonstrate dual activity against both MRSA and ovarian cancerPrecious I A Popoola, Thomas L Allam, Rebecca J Lilley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.Pageof 8